(including electronic publications). For this 7-month period, 6344 potentially interesting articles were screened to identify 121 controlled clinical trials (randomized controlled trials or quasi-randomized clinical trials) of therapeutic interventions in hematologic malignancies.
Clinical Background.
The HD2000 trial compared ABVD, BEACOPP, and cyclophosphamide, lomustine, vindesine, melphalan, prednisone, epidoxorubicin, vincristine, procarbazine, vinblastine, and bleomycin (CEC).
Contribution.
The study enrolled 307 previously untreated patients with advanced Hodgkin lymphoma.
They were randomly assigned to six courses of ABVD, to four escalated plus two standard courses of BEACOPP, or to six courses of CEC. After a median follow-up time of 41 months, patients treated with BEACOPP showed statistically significant better failure-free survival and progression-free survival than patients treated with ABVD. However, this better outcome of failure-free survival or progression-free survival by BEACOPP did not lead to improved overall survival for these patients. The survival curves of all three arms were similar. In addition, patients treated with BEACOPP showed lower risk of disease progression or relapse, but they also had more frequent severe treatment-related adverse events.
Implication for Practice.
Fewer cycles of BEACOPP escalated were used in this trial than in the BEACOPP trial discussed above. Although four escalated plus two standard courses of BEACOPP led to an improved progression-free survival, it is too early to determine whether there will be an improvement in overall survival.
Most Interesting Feature.
This is another trial that demonstrated superiority of BEACOPP escalated. Key study features are shown in Table 3 . This randomized controlled trial examined the effectiveness of azacitidine compared with the three most common conventional care regimens (best supportive care, low-dose cytarabine, or intensive chemotherapy). Patients older than 17 years of age with higher-risk myelodysplastic syndromes (international prognostic scoring system rating of intermediate-2 or high risk) were enrolled. They were randomly assigned to either six cycles of azacitidine (n = 179) or a predefined conventional care regimen (n = 179). Conventional care regimen was selected by the investigators before randomization (in the best supportive care regimen, 117 patients were randomly assigned to the azacitidine arm and 105 to the control arm; in the low-dose cytarabine regimen, 45 patients to the azacitidine arm and 49 to the control arm; for the intensive chemotherapy regimen, 17 patients to the azacitidine arm and 25 to the control arm). World Health Organization performance status of 0-2 were included. They were randomly assigned to up to a maximum of six courses of bendamustine (n = 162) or to six courses of chlorambucil (n = 157). Overall response rate, which was defined as the sum of complete and partial responses, was the primary endpoint. After a median follow-up time of 35 months (range = 1-68 months), the overall response rate was statistically significantly higher in the bendamustinetreated patients (68%) than in the chlorambucil-treated patients (31%) (P < .001). The progression-free survival was also statistically significantly improved in the bendamustine group (21.6 months) than in the chlorambucil group (8.3 months) (P < .001). However, after 3 years of follow-up, the observed overall survival tended to be better for the bendamustine group, but it was not statistically significant. Further trials with longer follow-up and more patients are needed to determine whether bendamustine improves overall survival compared with chlorambucil when used as a first-line treatment of chronic lymphocytic leukemia. This randomized controlled trial examined the effects of exercise training in patients, older than 17 years of age, with Hodgkin or non-Hodgkin lymphoma, who were receiving chemotherapy or no treatment. Baseline exercise was not a reason for exclusion, but patients were asked not to improve the training level during the time of study. Among the 122 patients (who are 9% of the 1306 screened and 26% of the 476 eligible patients), 60 were randomly assigned to supervised aerobic exercise training and 62 were randomly assigned to usual care. The primary endpoint was patient-rated physical functioning assessed by the Trial Outcome Index-Anemia. At the end of the 12 weeks of the training program, the exercise group was statistically significantly superior to usual care in terms of patient-rated physical functioning (mean group difference = 9.0, 95% CI = 2.0 to 16.0, P = .012), overall quality of life (P = .021), fatigue (P = .013), happiness (P = .004), depression (P = .005), general health (P = .001), cardiovascular fitness (P = .001), and lean body mass (P = .008). However, 6 months after the intervention ended, 63.6% of the exercise group and 40.0% of the usual care group reported self-managed regular exercise. At that time, exercise group was still statistically significantly superior to usual care for overall quality of life (P = .054), happiness (P = .034), and depression (P = .009). Interpretation of this study was challenging. The effect on quality of life was not mediated by the improvement in physical fitness. Therefore, other factors may have influenced the improvement in quality of life.
Other Interesting Trials
Suggestions given by the authors included increased social interaction and distraction from cancer and its treatments. Even if it is unclear which effects improve outcomes, an aerobic exercise program may have a positive influence on quality of life for lymphoma patients. 
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Contribution.
Erythropoiesis-stimulating agents reduce anemia in cancer patients and may improve quality of life, but there are concerns that erythropoiesis-stimulating agents might increase mortality.
Earlier reviews (17) (18) (19) (20) It was concluded that a new systematic review was needed to evaluate the old and the new evidence together and to determine the impact of erythropoiesis-stimulating agents on survival in cancer patients to see whether there are groups of patients who are at higher or lower risk than the average patient. To complete this study, the authors of this meta-analysis conducted an in-depth assessment of the individual patient data that was generated by the care of approximately 14 000 patients from 53 trials that were conducted worldwide. Data on each of these patients were provided by three companies that make erythropoiesis-stimulating agents (ie, Amgen, Johnson & Johnson, and Roche) and by several independent researchers (24-28). (The drug companies, however, had no role in conducting the meta-analysis.) The trials investigated one of the two types of erythropoiesis-stimulating agents (erythropoietin or darbepoetin) and compared the use of one of these drugs plus red blood cell transfusion (as needed) with red blood cell transfusion alone (as needed). Most patients were given their treatment while undergoing anticancer therapy (chemotherapy and/or radiation therapy), but other patients received treatment with an erythropoiesis-stimulating agent after they had completed their anticancer therapy. Some patients already had anemia; others were treated to prevent it. The patients had many different forms of cancer and had received many different anticancer treatments. The review showed that erythropoiesis-stimulating agents increased the on-study mortality (HR = 1.17, 95% CI = 1.06 to 1.30) and worsened overall survival (HR = 1.06, 95% CI = 1.00 to 1.12). The authors concluded that treatment with an erythropoiesis-stimulating agent shortened survival. They could not, however, identify with certainty any subgroup of patients at either increased or decreased risk of dying when taking erythropoiesis-stimulating agents.
Implications for Practice.
For patients undergoing chemotherapy, the increased mortality and worsened overall survival was less pronounced, but an adverse effect of erythropoiesis-stimulating agent could not be Authors stated that all analyses were conducted according to the intention-to-treat principle, but 86 patients were excluded from analysis after randomization. Details about these patients were given Outcomes Primary outcome = FFTF, defined as progression during treatment, lack of complete response at the end of treatment, relapse, or death from any cause Secondary outcomes = OS, response, or toxicity Results FFTF at 10 years: Statistically significant differences were found among the BEACOPP escalated arm (82%, 95% CI = 78% to 86%), the BEACOPP baseline arm (70%, 95% CI = 66% to 75%), and the COPP plus ABVD arm (64%, 95% CI = 58% to 70%) (P < .001). In the subgroup of patients aged >60 years, no FFTF differences were found in terms of FFTF between COPP plus ABVD and BEACOPP escalated Overall survival at 10 years: Statistically significant differences were found among the BEACOPP escalated arm (86%, 95% CI = 83% to 90%), the BEACOPP baseline arm (80%, 95% CI = 75% to 84%), and the COPP plus ABVD arm (75%, 95% CI = 70% to 81%) (P < .
001)
Complete response rate = 96% (95% CI = 93% to 97%) in the BEACOPP escalated arm, 88% (95% CI = 85% to 91%) in the BEACOPP baseline arm, and 85% (95% CI = 80% to 89%) in the and 71% (95% CI = 60% to 79%) in the CEC arm BEACOPP showed statistically significant improved PFS vs ABVD (P = .038). Estimated 5-year PFS = 68% (95% CI = 56% to 78%) in the ABVD arm, 81% (95% CI = 70% to 89%) in the BEACOPP arm, and 78% (95% CI = 68% to 86%) in the CEC arm Survival curves of the three arms were similar (P value not reported).
Estimated 5-year OS = 84% (95% CI = 69% to 92%) in the ABVD arm, 92% (95% CI = 84% to 96%) in the BEACOPP arm, and 91%
(95% CI = 81% to 96%) in the CEC arm Complete response rates were similar in the three arms (P = .207):
84% (95% CI = 76% to 91%) in the ABVD arm, 91% (95% CI = 85% to 97%) in the BEACOPP arm, and 83% (95% CI = 75% to 90%) in the CEC arm Safety Acute toxicity grade 3 or 4:
Anemia (5% in the ABVD arm, 16% in the BEACOPP escalated arm, and 15% in the CEC arm) (P = .038) Leukopenia (22% in the ABVD arm, 57% in the BEACOPP escalated arm, and 47% in the CEC arm) (P < .001) Neutropenia (34% in the ABVD arm, 54% in the BEACOPP escalated arm, and 48% in the CEC arm) (P = .016) Thrombocytopenia (3% in the ABVD arm, 22% in the BEACOPP escalated arm, and 17% in the CEC arm) (P < .001) Infections of grade 3 or 4 (2% in the ABVD arm, 14% in the Feature Details Secondary malignancies: four second malignancies (one in the ABVD arm, one in the BEACOPP arm, two in the CEC arm) Potential conflict of interest Author(s) indicated none *ABVD = doxorubicin, bleomycin, vinblastine, and dacarbazine; BEACOPP = bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone; CEC = cyclophosphamide, lomustine, vindesine, melphalan, prednisone, epidoxirubicin, vincristine, procarbazine, vinblastine, and bleomycin; CI = confidence interval; FFS = failure-free survival; OS = overall survival; PFS = progression-free survival.
